Orrick reports life science investments drop to lowest level since Q3 of 2019
Orrick‘s first quarter 2022 analysis of the life sciences sector shows a drop in investments – $11.7 billion across 407 deals. That is the lowest deal count since Q3 2019, but Orrick reports that “deal value was consistent with the elevated levels of the past two years.”
Other takeaways from the report, available here, are:
- Median pre-money valuations increased across all funding
stages examined (angel and seed, early stage venture capital (VC), and late stage VC). - Median deal sizes increased across all funding series except for Seed and Series B.
- The quarter saw modest exit activity totaling $5.0 billion
across 27 deals.
